SAGE Sage Therapeutics, Inc. Stock Quote

SAGE [NASD]

Index	-	P/E	-	EPS (ttm)	-10.35	Insider Own	0.10%	Shs Outstand	51.98M	Perf Week	-8.48%
Market Cap	5.39B	Forward P/E	-	EPS next Y	-2.66	Insider Trans	0.00%	Shs Float	51.11M	Perf Month	5.42%
Income	-537.50M	PEG	-	EPS next Q	-0.35	Inst Own	93.70%	Short Float	10.28%	Perf Quarter	31.67%
Sales	7.00M	P/S	769.75	EPS this Y	-65.50%	Inst Trans	0.51%	Short Ratio	7.73	Perf Half Y	88.73%
Book/sh	12.65	P/B	7.00	EPS next Y	64.40%	ROA	-59.80%	Target Price	97.55	Perf Year	25.67%
Cash/sh	10.99	P/C	8.06	EPS next 5Y	43.80%	ROE	-67.40%	52W Range	25.01 - 98.39	Perf YTD	2.36%
Dividend	-	P/FCF	-	EPS past 5Y	-51.60%	ROI	-75.00%	52W High	-10.00%	Beta	2.05
Dividend %	-	Quick Ratio	11.70	Sales past 5Y	-	Gross Margin	90.70%	52W Low	254.06%	ATR	4.06
Employees	675	Current Ratio	11.70	Sales Q/Q	-55.60%	Oper. Margin	-	RSI (14)	52.87	Volatility	5.35% 4.23%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	41.60%	Profit Margin	-	Rel Volume	0.73	Prev Close	92.44
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 BMO	Payout	-	Avg Volume	680.07K	Price	88.55
Recom	1.90	SMA20	-1.43%	SMA50	9.46%	SMA200	56.44%	Volume	497,839	Change	-4.21%

Jan-22-21

Downgrade

BMO Capital Markets

Outperform → Market Perform

$95

Jan-04-21

Upgrade

Guggenheim

Neutral → Buy

Jan-04-21

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$83 → $86

Dec-04-20

Upgrade

Mizuho

Neutral → Buy

$77 → $81

Dec-01-20

Downgrade

Raymond James

Outperform → Mkt Perform

Nov-16-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$87 → $85

Nov-06-20

Reiterated

H.C. Wainwright

Neutral

$76 → $81

Sep-11-20

Upgrade

Wedbush

Neutral → Outperform

Aug-10-20

Upgrade

Raymond James

Mkt Perform → Outperform

$70

May-08-20

Downgrade

Wedbush

Outperform → Neutral

Apr-08-20

Downgrade

Guggenheim

Buy → Neutral

Mar-18-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$73 → $60

Mar-06-20

Initiated

Citigroup

Buy

$71

Feb-28-20

Reiterated

H.C. Wainwright

Neutral

$87 → $78

Feb-06-20

Initiated

Mizuho

Neutral

Dec-06-19

Reiterated

RBC Capital Mkts

Outperform

$190 → $100

Dec-05-19

Reiterated

Guggenheim

Buy

$200 → $110

Dec-05-19

Downgrade

SunTrust

Buy → Hold

Oct-30-19

Initiated

H.C. Wainwright

Neutral

$160

May-23-19

Initiated

Wedbush

Outperform

Jan-07-21 06:30AM	Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference Business Wire
Jan-04-21 10:04AM	Benzinga's Top Upgrades, Downgrades For January 4, 2021 Benzinga
Dec-23-20 06:30AM	Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 Business Wire
Dec-22-20 09:39AM	Is SAGE A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-20-20 04:00AM	Industry Analysts Just Upgraded Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Forecasts By 23% Simply Wall St.
Dec-19-20 07:46AM	Should You Buy Sage Stock After the Biogen Investment? Motley Fool
Dec-18-20 06:45AM	Where Will Biogen Be in 5 Years? Motley Fool +6.73%
Dec-16-20 06:30AM	Sage Therapeutics Announces the Appointment of Barry Greene as CEO Business Wire
Dec-12-20 07:20AM	3 Stocks That Are Giving Their Investors Coal in Their Stockings Motley Fool
Dec-09-20 07:54AM	Is Biogen Getting Desperate? Motley Fool
Dec-04-20 09:32AM	What Will Biogen Do If Its Alzheimer's Drug Goes South? Investor's Business Daily
Dec-03-20 04:30PM	Sage Therapeutics to Present at BMO 2020 Growth & ESG Conference Business Wire
Dec-02-20 12:56PM	Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More Zacks -5.60%
12:07AM	This Just In: Analysts Are Boosting Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Outlook for Next Year Simply Wall St.
Dec-01-20 11:55AM	Sage Therapeutics Draws Negative Commentary on Biogen Deal TheStreet.com
Nov-30-20 10:42AM	Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies Zacks
Nov-29-20 09:32AM	Sage Therapeutics Inks $1.5 Billion Development Deal with Biogen; Mizuho Stays Sidelined TipRanks
Nov-27-20 01:18PM	Sage Therapeutics Dives On $1.5 Billion Collaboration Deal With Biogen Investor's Business Daily -8.62%
11:25AM	Sage Gets $3 Billion Endorsement of Its Depression Drugs From Biogen Barrons.com
08:42AM	Sage to Get $1.53 Billion From Biogen for Depression Drug Development TheStreet.com
08:04AM	UPDATE: Sage Therapeutics to receive $1.525 billion in cash in deal with Biogen to jointly develop depression, tremor therapies MarketWatch
07:30AM	Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders GlobeNewswire
Nov-18-20 12:04AM	Some Analysts Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Estimates Simply Wall St.
Nov-09-20 08:26AM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
Nov-05-20 09:31PM	Sage Therapeutics Inc (SAGE) Q3 2020 Earnings Call Transcript Motley Fool
08:56AM	Sage Therapeutics: Q3 Earnings Insights Benzinga
06:30AM	Sage Therapeutics Announces Third Quarter 2020 Financial Results and Highlights Pipeline and Business Progress Business Wire
Nov-02-20 06:30AM	Sage Therapeutics to Present at Upcoming November Investor Conferences Business Wire
Oct-22-20 06:30AM	Sage Therapeutics Announces Chief Executive Jeff Jonas to Undergo Scheduled Medical Procedure Business Wire +5.31%
Oct-21-20 11:09AM	We're Not Very Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Rate Simply Wall St.
Oct-19-20 05:00PM	Sage Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 Business Wire
Oct-15-20 06:30AM	Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD Business Wire
Oct-01-20 07:00AM	Sage Therapeutics Appoints Barry Greene to Board of Directors Business Wire
Sep-16-20 04:55PM	SAGE Therapeutics Inc (SAGE): Hedge Funds In Wait-and-See Mode Insider Monkey
Sep-15-20 09:56AM	Sage Therapeutics (NASDAQ:SAGE) Share Prices Have Dropped 65% In The Last Year Simply Wall St.
Sep-11-20 01:38PM	Sage Therapeutics Upgraded on Potential for Depression Drug TheStreet.com
09:38AM	Benzinga's Top Upgrades, Downgrades For September 11, 2020 Benzinga
08:41AM	Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher Zacks
Sep-10-20 06:30AM	Sage Therapeutics FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises Business Wire +5.14%
Sep-01-20 06:30AM	Sage Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Aug-20-20 04:31PM	Sage Therapeutics to Host Sage FutureCast Webcast Business Wire
Aug-10-20 05:31PM	Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcript Motley Fool +5.15%
07:20AM	Recap: Sage Therapeutics Q2 Earnings Benzinga
07:01AM	Have Insiders Been Buying Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares? Simply Wall St.
06:30AM	Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress Business Wire
Jul-30-20 06:30AM	Sage Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
Jul-21-20 06:30AM	Sage Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 Business Wire
Jul-13-20 10:22AM	Did Hedge Funds Make The Right Call On SAGE Therapeutics Inc (SAGE) ? Insider Monkey
Jun-24-20 03:58PM	Edited Transcript of SAGE earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-17-20 04:04PM	Neurocrine Adds to Pipeline With $2 Billion Takeda Deal GuruFocus.com
Jun-10-20 08:37PM	Should You Avoid SAGE Therapeutics Inc (SAGE)? Insider Monkey
Jun-09-20 09:55AM	Is There Any Hope Left for Sage Therapeutics? Motley Fool
Jun-01-20 06:30AM	Sage Therapeutics to Present at Goldman Sachs 41st Annual Global Healthcare Conference Business Wire
May-09-20 05:01PM	Sage Therapeutics Inc (SAGE) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 06:30AM	Sage Therapeutics to Present at Bank of America Health Care Conference 2020 Business Wire
May-07-20 04:01PM	Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress Business Wire
May-03-20 07:30PM	One Biotech Stock For 2020 Oilprice.com
Apr-22-20 11:09AM	The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics Zacks
Apr-21-20 07:39AM	Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results Zacks
Apr-20-20 07:48AM	Sage Therapeutics' Shares March Higher, Can It Continue? Zacks +10.60%
Apr-16-20 06:30AM	Sage Therapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020 Business Wire
Apr-13-20 10:51AM	How Sage Therapeutics (SAGE) Stock Stands Out in a Strong Industry Zacks
Apr-08-20 12:29PM	Sage Therapeutics Slash Staff by Half TheStreet.com
10:47AM	Sage Therapeutics Lays Off Staff to Save Cash After Failed Drug Trial Barrons.com
07:53AM	Sage to restructure, let go of 340 workers MarketWatch
06:10AM	Sage slashes 53% of staff as hospitals cut inpatient stays American City Business Journals
06:09AM	Here are Mass. companies that have laid off or furloughed workers American City Business Journals
04:34AM	SAGE Announces Massive Restructuring To Focus On Failed Depression Drug SmarterAnalyst
Apr-07-20 04:01PM	Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline Business Wire
08:37AM	Sage Therapeutics (SAGE) in Focus: Stock Moves 9.3% Higher Zacks
Apr-03-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-27-20 02:53PM	Hedge Funds Were Buying SAGE Therapeutics Inc (SAGE) Before The Coronavirus Insider Monkey
Mar-20-20 08:30PM	An Egg Stock That Looks Tasty, Especially Now Barrons.com -5.64%
Mar-19-20 06:57PM	Edited Transcript of SAGE earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Mar-18-20 06:30AM	Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration Business Wire
Mar-12-20 08:45AM	Why Sage Therapeutics (SAGE) Stock Might be a Great Pick Zacks -17.99%
Mar-11-20 07:00AM	Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano GlobeNewswire -8.62%
Mar-04-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-02-20 09:59AM	Sage Therapeutics Stock Is a Steal, Analyst Says Barrons.com +13.53%
07:24AM	Sage Therapeutics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
Feb-27-20 07:39PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud GlobeNewswire -18.29%
06:30AM	Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress Business Wire
Feb-26-20 08:31AM	Why Earnings Season Could Be Great for Sage Therapeutics (SAGE) Zacks
Feb-25-20 12:03PM	The Sage Therapeutics (NASDAQ:SAGE) Share Price Is Up -56% And Shareholders Are Holding On Simply Wall St.
Feb-24-20 06:30AM	Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference Business Wire
Feb-10-20 06:30AM	Sage Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 Business Wire
Feb-04-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-03-20 11:27AM	Andreas Halvorsen Trims Adaptive Biotechnologies Stake GuruFocus.com
Jan-17-20 08:40AM	An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 30% Undervalued Simply Wall St.
Jan-09-20 08:44AM	Hedge Fund Favorites vs. SAGE Therapeutics Inc (SAGE) In 2019 Insider Monkey
Jan-03-20 04:30PM	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-29-19 03:24AM	Corporate Insiders Pull the Trigger on 3 Buy-Rated Stocks TipRanks
Dec-23-19 02:47PM	Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
06:30AM	Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020 Business Wire
Dec-19-19 03:07PM	Minerva shares fall on failed depression drug trial MarketWatch
Dec-16-19 11:28AM	Weekly CEO Buys Highlight GuruFocus.com
Dec-14-19 02:56PM	Notable Insider Buys In The Past Week: Enterprise Products Partners, PBF Energy, Sage Therapeutics Benzinga
Dec-12-19 08:15PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened ACCESSWIRE +5.71%
10:38AM	Trade Alert: The Chief Scientific Officer Of Sage Therapeutics, Inc. (NASDAQ:SAGE), Albert Robichaud, Has Just Spent US$1.6m Buying Shares Simply Wall St.
Dec-11-19 08:01PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened GlobeNewswire +8.50%

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IGUCHI KIMI	CFO & Treasurer	Jan 05	Option Exercise	1.36	1,750	2,380	35,355	Jan 06 04:23 PM
IGUCHI KIMI	CFO & Treasurer	Apr 30	Option Exercise	1.36	4,000	5,440	33,261	May 04 04:53 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience